NCT07527403 Impact of Theta Burst Repetitive Transcranial Magnetic Stimulation on the Patient's Self-reported Improvement in Their Motor Functional Neurological Disorder
| NCT ID | NCT07527403 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Center Guillaume Régnier |
| Condition | Functional Neurological Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 22 participants |
| Start Date | 2026-03-13 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 22 participants in total. It began in 2026-03-13 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Functional neurological disorder (FND) is a condition that causes significant suffering and disability. It is defined by the presence of neurological symptoms that interfere with an individual's functioning and are not consistent with any known anatomical lesion but that causes significant functional impairment. The investigators are particularly interested in motor symptoms (abnormal movements or motor deficits). Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and acceptable treatment that has proven effective in certain chronic pain conditions, depression, and OCD. The investigators would like to evaluate the impact of rTMS on the patient's overall perception of change, particularly on the clinical symptoms of motor FND. Secondary objectives include evaluating the overall effect on symptoms from the clinician's perspective, the effect on quality of life, on depressive and anxiety symptoms and associated dissociation, as well as evaluating any changes in the sense of agency and identifying the side effects of rTMS treatment.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 * Patients with FND, either deficits or abnormal movements, diagnosed by a neurologist. * Patients with an indication for validated neuronavigated rTMS treatment. * Patients who have indicated that they do not object to participating in the study. Exclusion Criteria: * Patients subject to legal protection (legal guardianship, conservatorship, trusteeship) * Patients deprived of liberty
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07527403 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Functional Neurological Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07527403 currently recruiting?
Yes, NCT07527403 is actively recruiting participants. Contact the research team at d.drapier@ch-guillaumeregnier.fr for enrollment information.
Where is the NCT07527403 trial being conducted?
This trial is being conducted at Rennes, France.
Who is sponsoring the NCT07527403 clinical trial?
NCT07527403 is sponsored by Hospital Center Guillaume Régnier. The trial plans to enroll 22 participants.